Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ipilimumab N01 + sintilimab + platinum chemotherapy in first-line NSCLC with SMARCA4/STK11/KEAP1 alterations
ChiCTR2600131208Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and sintilimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ipilimumabsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600131208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131208.